Genentech Aims To Extend Avastin Duration Of Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Physicians have been treating first-line colorectal cancer patients for less time than the product was used for in clinical trials, Exec VP Clark says.
You may also be interested in...
Roche Files Avastin EU Marketing Authorization Application For NSCLC
An sBLA for the oncologic in non-small cell lung cancer is already pending in the U.S.
Roche Files Avastin EU Marketing Authorization Application For NSCLC
An sBLA for the oncologic in non-small cell lung cancer is already pending in the U.S.
Avastin Approved For Second-Line CRC
Genentech's Avastin gained approval June 20 for use in second-line treatment of metastatic colorectal cancer as an adjunct to chemotherapy, FDA said